Myelodysplastic Syndrome

Why trials studying Myelodysplastic Syndrome stopped, in this sample of ClinicalTrials.gov.

17 stopped trials with a clear reason; 76% ended for non-scientific reasons.

Trials

• Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia
  NCT04994808 · TERMINATED · funding or business
  “The study was closed due to the end of funding.”
• Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation
  NCT03602898 · WITHDRAWN · funding or business
  “Insufficient funding”
• Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory
  NCT03969446 · SUSPENDED · slow enrollment
  “Accrual goal Met”
• Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
  NCT03150004 · TERMINATED · funding or business
  “No longer have funding support to complete the pharmacogenetics component.”
• Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia
  NCT03195010 · TERMINATED · slow enrollment
  “Terminated because of slow recruitment and lack of funding support”
• Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome
  NCT02676323 · TERMINATED · slow enrollment
  “Slow accrual”
• Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia
  NCT02381548 · TERMINATED · safety
  “Other - Adverse Events”
• Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant
  NCT02065869 · TERMINATED · funding or business
  “Sponsor decision”
• Phase I Study of Milatuzumab for Graft Versus Host Disease
  NCT01663766 · TERMINATED · slow enrollment
  “PIs agreed no safety signals were shown, drug did not appear to lessen the risk of preventing GVHD no further patients would be enrolled”
• Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
  NCT01643603 · TERMINATED · slow enrollment
  “Study terminated due to slow accrual.”
• ED-TBI Followed By Allogeneic Stem Cell Transplantation For The Treatment Of Refractory AML And Advanced MDS
  NCT01709396 · SUSPENDED · futility
  “initial on hold due to space but now permanently suspended due to futility.”
• Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
  NCT01028716 · TERMINATED · slow enrollment
  “The study experienced lower accrual rates after the onset of COVID. Upon review of the collected data it was deemed that an adequate amount of subjects has been enrolled to date to assess study aims.”
• Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia
  NCT00867308 · TERMINATED · futility
  “Lack of efficacy”
• Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
  NCT00818649 · TERMINATED · safety
  “Met protocol stop rule \[i.e., extreme toxicity\]”
• A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients
  NCT00699842 · TERMINATED · regulatory or ethics
  “Administratively terminated per FDA recommendation”
• Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies
  NCT00113828 · TERMINATED · slow enrollment
  “Insufficient accrual”
• Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
  NCT00074490 · TERMINATED · slow enrollment
  “Premature closure due to inability to accrue to ARM IVD, cohorts 1 and 2”

Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.